Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY2562175 是一种有效的选择性 FXR 激动剂,其EC50值为 193 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 972 | 现货 | ||
2 mg | ¥ 1,380 | 现货 | ||
5 mg | ¥ 2,170 | 现货 | ||
10 mg | ¥ 3,520 | 现货 | ||
25 mg | ¥ 6,900 | 现货 | ||
50 mg | ¥ 9,490 | 现货 | ||
100 mg | ¥ 12,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,580 | 现货 |
产品描述 | LY2562175 is an effective and selective FXR agonist (EC50: 193 nM). |
靶点活性 | FXR:(EC50)193 nM |
体外活性 | LY2562175 boosts transcriptional activation of human FXR in a cell-based co-transfection assay (EC50: 193 nM) and it also promotes the recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 (a relative EC50: 121 nM). It has 93.5% efficacy as compare to GW4064. |
体内活性 | LY2562175 induces a dose-dependent decrease in serum cholesterol and serum triglycerides. LY2562175(female ZDF rats) treatment, causes a dose-dependent lowering of plasma triglycerides in the fasted and nonfasted states. LY2562175 further lowers fasted and nonfasted plasma triglycerides when administered as a fixed-dose combination with BRL49653. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from the control group. The ED50 for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. FPLC fractionation of the lipoproteins shows that LY2562175 treatment causes a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model. |
分子量 | 540.44 |
分子式 | C28H27Cl2N3O4 |
CAS No. | 1103500-20-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 0.1 mg/mL (insoluble)
DMSO: 62.5 mg/mL (115.65 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8503 mL | 9.2517 mL | 18.5034 mL | 46.2586 mL |
5 mM | 0.3701 mL | 1.8503 mL | 3.7007 mL | 9.2517 mL | |
10 mM | 0.185 mL | 0.9252 mL | 1.8503 mL | 4.6259 mL | |
20 mM | 0.0925 mL | 0.4626 mL | 0.9252 mL | 2.3129 mL | |
50 mM | 0.037 mL | 0.185 mL | 0.3701 mL | 0.9252 mL | |
100 mM | 0.0185 mL | 0.0925 mL | 0.185 mL | 0.4626 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LY2562175 1103500-20-4 Autophagy Metabolism FXR NR1H4 Inhibitor LY 2562175 inhibit LY-2562175 inhibitor